Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)

NCT ID: NCT03186209

Last Updated: 2024-04-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 695 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-09-07
• Study Completion Date: 2023-01-30

Brief Summary

This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma exacerbations and uncontrolled asthma receiving medium to high-dose inhaled corticosteroid plus long-acting β2-agonist (ICS-LABA) with or without oral corticosteroids and additional asthma controllers.

Detailed Description

Approximately 666 patients will be randomised. Patients will be stratified by country/region, age group (adult or adolescent), and peripheral blood eosinophil count at time of Visit 1 (<300 or ≥300 cells/μL).All the patients will be randomised to either placebo or benralizumab (1:1 ratio) for a 48-weeks treatment, every 4 weeks for the first 3 doses and then every 8 weeks thereafter.

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Benralizumab

Benralizumab administered subcutaneously

Group Type: EXPERIMENTAL

Benralizumab

Intervention Type: BIOLOGICAL

Benralizumab subcutaneously on study week 0 until study week 40 inclusive.

Placebo

Placebo administered subcutaneously

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: BIOLOGICAL

Placebo subcutaneously on study week 0 until study week 40 inclusive.

Interventions

Benralizumab

Benralizumab subcutaneously on study week 0 until study week 40 inclusive.

Intervention Type: BIOLOGICAL

Placebo

Placebo subcutaneously on study week 0 until study week 40 inclusive.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Written informed consent, and assent when applicable for study participation must be obtained prior to any study related procedures being performed (local regulations are to be followed in determining the assent/consent requirements for children and parent[s]/guardian[s]) and according to international guidelines and/or applicable local guidelines.

2. Female and male aged 12 to 75 years, inclusively, at the time of Visit 1. For those patients, who are 17 on the day of Visit 1 but will turn 18 after this day, will be considered an adolescent for the purposes of this trial.

3. History of physician-diagnosed asthma requiring treatment with medium-to-high dose ICS (>250μg fluticasone propionate dry powder formulation equivalents total daily dose) and a LABA, for at least 6 months prior to Visit 1.

4. Additional maintenance asthma controller medications that are locally approved in a country for the treatment of asthma (e.g., leukotriene receptor antagonists (LTRAs), tiotropium, chromone, theophylline, oral corticosteroid), and have been used for at least 30 days prior to Visit 1 are allowed.

5. At least 2 documented asthma exacerbations in the 12 months prior to the date informed consent, and assent when available, during the treatment of medium-to-high dose ICS-LABA that required use of a systemic corticosteroid or a temporary increase from the patient's usual maintenance dose of oral corticosteroid. For patients who are re-screened within 30 days of their screen failure date, the calculation of the 12 month period should be done from the original informed consent, and assent when applicable date.

6. Documented post-bronchodilator (post-BD) reversibility in FEV1 of >12% and >200 mL in FEV1 within 12 months prior to Visit 1. If historical documentation is not available, reversibility must be demonstrated and documented at Visit 2.

7. Fulfilment of at least 1 of the following conditions over the 7 days prior to randomization:

• >2 days with a daytime or night time symptoms score >1
• Rescue Short-acting β2 agonist (SABA) use on >2 days
• ≥1 nocturnal awakening due to asthma

8. Pre-bronchodilator (Pre-BD) FEV1 of <80% predicted (<90% predicted for patients aged 12 to 17 years) at Visit 2.

9. ACQ-6 score > = 1.5 at Visit 2.

Exclusion Criteria

1. Known history of clinically important pulmonary disease other than asthma (e.g., active lung infection, chronic obstructive pulmonary disease (COPD), bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g,. allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).

2. Known history of any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:

• Affect the safety of the patient throughout the study
• Influence the findings of the studies or their interpretations
• Impede the patient's ability to complete the entire duration of study.

3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent, and assent when applicable, is obtained or during the screening period.

4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study.

5. Current smokers or former smokers with a smoking history of > 10 pack-years.

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Research Site

Baotou, , China

Research Site

Beijing, , China

Research Site

Beijing, , China

Research Site

Beijing, , China

Research Site

Beijing, , China

Research Site

Beijing, , China

Research Site

Changsha, , China

Research Site

Changsha, , China

Research Site

Changzhi, , China

Research Site

Chengdu, , China

Research Site

Chengdu, , China

Research Site

Chongqing, , China

Research Site

Foshan, , China

Research Site

Ganzhou, , China

Research Site

Guangzhou, , China

Research Site

Guangzhou, , China

Research Site

Guangzhou, , China

Research Site

Guangzhou, , China

Research Site

Guiyang, , China

Research Site

Haikou, , China

Research Site

Hangzhou, , China

Research Site

Hangzhou, , China

Research Site

Hangzhou, , China

Research Site

Hangzhou, , China

Research Site

Hohhot, , China

Research Site

Hohhot, , China

Research Site

Jining, , China

Research Site

Kunming, , China

Research Site

Kunming, , China

Research Site

Lishui, , China

Research Site

Nanchang, , China

Research Site

Nanjing, , China

Research Site

Nanjing, , China

Research Site

Nanjing, , China

Research Site

Neijiang, , China

Research Site

Qingdao, , China

Research Site

Qingdao, , China

Research Site

Shanghai, , China

Research Site

Shanghai, , China

Research Site

Shanghai, , China

Research Site

Shanghai, , China

Research Site

Shanghai, , China

Research Site

Shenyang, , China

Research Site

Shenyang, , China

Research Site

Taiyuan, , China

Research Site

Taizhou, , China

Research Site

Wanzhou, , China

Research Site

Wuhan, , China

Research Site

Xiangtan, , China

Research Site

Xinxiang, , China

Research Site

Xuzhou, , China

Research Site

Xuzhou, , China

Research Site

Yangzhou, , China

Research Site

Yinchuan, , China

Research Site

Yinchuan, , China

Research Site

Zhanjiang, , China

Research Site

Zhuhai, , China

Research Site

Zunyi, , China

Research Site

Iloilo City, , Philippines

Research Site

Manila, , Philippines

Research Site

Bucheon-si, , South Korea

Research Site

Busan, , South Korea

Research Site

Cheonan, , South Korea

Research Site

Daejeon, , South Korea

Research Site

Gwangju, , South Korea

Research Site

Seongnam-si, , South Korea

Research Site

Seoul, , South Korea

Research Site

Seoul, , South Korea

Research Site

Seoul, , South Korea

Research Site

Seoul, , South Korea

Research Site

Seoul, , South Korea

Research Site

Seoul, , South Korea

Research Site

Suwon, , South Korea

Research Site

Uijeongbu-si, , South Korea

Research Site

Wŏnju, , South Korea

Research Site

Taipei, , Taiwan

Research Site

Taipei, , Taiwan

Research Site

Taipei, , Taiwan

Research Site

Taoyuan, , Taiwan

Countries

China; Philippines; South Korea; Taiwan

References

Jin Y, Guiastrennec B, Stuke M, Yao Y, Zhang Y, Barker P, Jison M, Penland RC, Ding J, Lukka PB. Population Pharmacokinetics and Exposure-Response Analysis of Benralizumab in Chinese Adults, Adolescents, and Pediatric Participants with Severe Eosinophilic Asthma. Clin Pharmacokinet. 2025 Aug;64(8):1231-1243. doi: 10.1007/s40262-025-01538-9. Epub 2025 Jun 23.

Reference Type: DERIVED

PMID: 40551003 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00036&amp;attachmentIdentifier=94f140e1-8d12-441f-a36f-47b7a861e52c&amp;fileName=5Sep2023-d3250c00036-csp-v5_Redacted_.pdf&amp;versionIdentifier=

Redacted CSP

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00036&amp;attachmentIdentifier=cc47324b-7f06-401d-a8ed-a6a71fd95944&amp;fileName=d3250c00036-sap-ed3_Redacted_5Sep2023.pdf&amp;versionIdentifier=

Redacted SAP

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00036&amp;attachmentIdentifier=2640ddf4-529a-41b1-877d-3d53a0495d8a&amp;fileName=d3250c00036-study-synopsis_Redacted_5Sep2023.pdf&amp;versionIdentifier=

Redacted CSR Synopsis

Other Identifiers

2017-000702-38

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

D3250C00036

Identifier Type: -

Identifier Source: org_study_id